OTC · Drug Manufacturers - Specialty & Generic

RIV Capital Inc. (CNPOF) Stock

$0.08 +0.00% OTC: CNPOF Healthcare

RIV Capital Inc., previously known as Canopy Rivers Inc., functions as a venture capital firm. Although it employs a flexible investment strategy, engaging with companies from initial seed stages through to commercial sale, it primarily favors Series A to C funding rounds.

Valuation

MetricValue
Price$0.08
Market Cap$10.96M
P/E Ratio-0.15
P/B Ratio0.23
P/S Ratio1.73
EPS (TTM)$-0.48
52-Week High$0.17
52-Week Low$0.06
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-112.58%
ROA-38.86%
ROCE-43.06%
Gross Margin-3.07%
Operating Margin-1433.33%
Net Margin-1083.33%
Debt/Equity2.94
Current Ratio5.01

Annual Financials (USD)

Metric20202021202220232024
Revenue$10.0M$13.0M$2.0M$7.0M$6.0M
Operating Profit$-42.0M$-24.0M$-44.0M$-23.0M$-86.0M
Net Profit$-106.0M$-42.0M$-179.0M$-80.0M$-65.0M
EPS$-0.75$-0.30$-1.09$-0.59$-0.48
Op Margin-415.5%-181.4%-1835.5%-335.6%-1516.5%

Balance Sheet (USD)

Metric20202021202220232024
Total Assets$266.0M$335.0M$262.0M$262.0M$219.0M
Total Liabilities$19.0M$24.0M$153.0M$153.0M$177.0M
Cash$101.0M$319.0M$77.0M$81.0M$82.0M
Borrowings$0$81.0M$110.0M$110.0M$124.0M

Latest News

Syngenta's $5 Billion Hong Kong IPO Faces Delay Until 2027 GuruFocus.com · Jul 16, 2026 Apollo's 715p EasyJet Bid Forces Castlelake Into Higher-Offer Decision GuruFocus.com · Jul 16, 2026 Uber's $14.8 Billion Delivery Hero Deal Expands Global Reach to 99 Markets GuruFocus.com · Jul 16, 2026 TSMC Targets 40%+ Sales Growth, Lifts 2026 Capex to $64 Billion GuruFocus.com · Jul 16, 2026 Alibaba Jumps 7.9% as Apple Intelligence Approval Revives China Tech Rally GuruFocus.com · Jul 16, 2026

Cash Flow (USD)

Metric20202021202220232024
Operating Cash Flow$-6.0M$-23.0M$-23.0M$-12.0M$-12.0M
Investing Cash Flow$-51.0M$89.0M$-239.0M$-240.0M$15.0M
Financing Cash Flow$0$150.0M$-4.0M$-4.0M$-26.0M
Net Cash Flow$-57.0M$216.0M$-241.0M$-241.0M$-221.0M
Free Cash Flow$-6.0M$-22.0M$-28.0M$-17.0M$-15.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-3.39
FCF Yield-196.39%
Quick Ratio4.48
Interest Coverage0.00
Return 1Y
Return 3Y
Return 5Y

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ACRDFAcreage Holdings, Inc. $0.12 +2.52% -0.01 $4.88M 0.00%
ATBPFAntibe Therapeutics Inc. $0.22 -0.19% -0.80 $11.43M 0.00%
LVCLYLiving Cell Technologies Limited $0.03 +24.39% -11.54 $11.39M 0.00%
LXXGFLexaGene Holdings Inc. $0.08 +0.00% -0.89 $11.34M 0.00%
MGCLFMGC Pharmaceuticals Limited $0.27 +2.88% -0.06 $12.11M 0.00%

About RIV Capital Inc.

RIV Capital Inc., previously known as Canopy Rivers Inc., functions as a venture capital firm. Although it employs a flexible investment strategy, engaging with companies from initial seed stages through to commercial sale, it primarily favors Series A to C funding rounds. The company's core focus is the expanding cannabis industry, specifically targeting promising marijuana enterprises. Its investment interests span numerous sub-sectors within the cannabis ecosystem, including agriculture and food sciences, production, processing, pharmaceuticals and biotechnology, software and data, hardware, consumer products and accessories, wellness products, retail and distribution, as well as media and content. The firm also allocates capital to specific product categories such as beverages, capsules and concentrates, edibles, dry flower/pre-rolls, vaporizers and hardware, pet products, and topical applications. Within agriculture and food sciences, RIV Capital supports advancements in plant, soil, food, animal, and environmental sciences. Its production investments encompass various cultivation methods like indoor, greenhouse, outdoor, and nursery cultivation, along with fermentation. In processing, the firm backs activities including harvesting, extraction and purification, packaging, food and beverage processing, and laboratory testing services. For pharmaceuticals and biotechnology, areas of focus include drug discovery and development, diverse delivery methods (e.g., pills, soft gels, tinctures), biosynthetically derived cannabinoids and other molecules, medical devices (e.g., inhalers), and laboratory equipment. Consumer product interests extend to edibles, beverages, inhalables, cosmetics, and accessories for cannabis consumption. In retail and distribution, the firm targets licensed brick-and-mortar stores, pharmacies, online marketplaces, and delivery services. RIV Capital actively pursues investment opportunities on a global scale. While its historical investment amounts have varied from CA$1 million ($0.71 million) to CA$40 million ($28.45 million), typical investments generally fall within the range of CA$5 million ($3.6 million) to CA$10 million ($7.1 million). The firm predominantly seeks to acquire minority stakes and utilizes a variety of investment instruments, such as debt, preferred and common equity, and production-linked royalties. RIV Capital Inc. was established in 2017 and operates from its headquarters in Toronto, Canada.

RIV Capital Inc. is headquartered in CA.

RIV Capital Inc. (CNPOF) stock trades at $0.08 with a market capitalization of $10.96M. The stock is valued at a price-to-earnings (P/E) ratio of -0.15, price-to-book of 0.23, price-to-sales of 1.73. Over the past 52 weeks the stock has ranged between $0.06 and $0.17, and currently trades 52.9% below its 52-week high.

On profitability, RIV Capital Inc. generates a return on equity (ROE) of -112.58%, return on capital employed of -43.06%, an operating margin of -1433.33%, a net profit margin of -1083.33%.

Official website: www.rivcapital.com

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides